Why is the titration interval four weeks and not two?

The label documentation for the agent in question is ambiguous on exactly this point.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

Why does this happen, and what would falsify the usual explanation?

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

The top of the schedule is not the target. The working dose is.

Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

On the detail: the dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

Four half-lives between steps, minimum. Work it out for your agent.

edited 17 Nov 2025 by halvard_ness — reworded for clarity after a comment

The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Stepping back is a normal adjustment, not a failure.

This is the single most consequential controllable variable in the whole experience, and people routinely rush it.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.

Slower costs time and nothing else. The ceiling is the same.